Licepler

Eplerenone, the active ingredient in Licepler, is a selective aldosterone receptor antagonist presented as an oral tablet for oral use. It is employed in the management of hypertension and heart failure, helping to control blood pressure and reduce fluid overload in affected patients.

GNH USA supplies Licepler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Eplerenone acts on the mineralocorticoid pathway to treat cardiovascular conditions. - Hypertension: lowers blood pressure by reducing sodium retention and vascular volume. - Heart failure with reduced ejection fraction: improves survival and decreases hospitalizations by mitigating cardiac remodeling. - Post‑myocardial infarction with left ventricular dysfunction: reduces the risk of cardiovascular death and heart‑failure progression.

Eplerenone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hyperkalemia: elevated blood potassium levels. - Dizziness or light‑headedness. - Headache. - Fatigue. - Nausea or gastrointestinal discomfort. - Diarrhea.

Serious or Rare Side Effects: - Severe hyperkalemia leading to cardiac arrhythmia. - Acute renal failure or significant decline in kidney function. - Angioedema or severe allergic reaction. - Hepatic dysfunction with elevated liver enzymes. - Marked hypotension. - Life‑threatening anaphylaxis.

Before initiating therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Monitor potassium: check serum K+ regularly, especially in renal impairment. - Assess renal function: evaluate creatinine and eGFR before and during treatment. - Caution in diabetes: increased risk of hyperkalemia. - Avoid in severe hepatic impairment: drug clearance may be reduced. - Contraindicated in patients with baseline hyperkalemia. - Store at ambient temperature: keep in the original pack, protect from moisture.

Eplerenone interacts with several drug classes that can alter potassium balance or renal function.

Major Interactions (Avoid): - Potassium‑sparing diuretics (e.g., spironolactone, amiloride): additive hyperkalemia risk. - ACE inhibitors or ARBs: synergistic increase in serum potassium. - Potassium supplements or salt substitutes containing KCl. - Cyclosporine: may raise eplerenone levels.

Moderate Interactions (Monitor Closely): - NSAIDs: can impair renal function and raise potassium. - Thiazide diuretics: may affect electrolyte balance. - Digoxin: monitor for toxicity if hyperkalemia occurs. - Lithium: altered lithium clearance may require dose adjustment.